3SOF

All she is lacking right now is volume

AP
Hollis-Eden Up on Cancer Study Data
Friday September 7, 9:08 am ET 
Hollis-Eden Shares Rise on Data Showing Lasting Effectiveness of Breast Cancer Drug


SAN DIEGO (AP) -- Shares of Hollis-Eden Pharmaceuticals Inc. jumped in Friday premarket trading after the company said data from an animal study showed its cancer drug candidate, HE3235, continued to prevent breast cancer tumor growth even after dosing ended.


The stock surged 33 cents, or 20 percent, to $1.97 in premarket trading, having closed Thursday at $1.64. Shares have ranged between $1.42 and $7.49 over the past year.

At the ASCO Breast Cancer Symposium in San Francisco, Hollis-Eden presented prior data that showed HE3235 significantly inhibited new tumors and stopped the growth of existing tumors in a preclinical breast cancer study involving rats.

The company said updated data shows that existing tumors in these HE3235-treated animals didn't progress and no new tumors were reported during the five weeks of observation after dosing stopped, in contrast to vehicle-treated animals in which tumors continued to grow.

"The new data indicating that the anti-tumor benefit of HE3235 was sustained for five weeks after dosing stopped are striking in light of the fact that approved breast cancer treatments lose activity once treatment is discontinued," the company said in a statement.

Hollis-Eden plans to file an investigational new drug application with the Food and Drug Administration in the first quarter of 2008 in order to initiate a planned Phase I/II clinical cancer trial with HE3235.

"The lasting anti-tumor effect of HE3235 reported in this animal model of breast cancer suggests the compound is causing tumor cells to undergo apoptosis, or die," said Richard B. Hollis, chairman and CEO of Hollis-Eden. "Therefore, the compound may act through a novel mechanism of action that could make it useful in treating multiple types of cancer."

Currently the leading approved drug treatments for prostate or breast cancer focus on blocking the effects of testosterone or estrogen, and generate annual sales of $500 million to $2 billion.


52wk Range: 1.42 - 7.49
Volume: 9,103,769
Avg Vol (3m): 261,944

Technicals
Close Above the 50-day MA
Most Actives
Gap Up
Percentage Gainer

Last Price Quote is:
38.33%above 13-day MA
29.50%above 50-day MA
RS Rating: 47 

Fundamentals
Key Data:
Market Cap (M): $66.91 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: 11/09/2007
Last Analyst Rating: Mkt Outperform

ANNOUNCES POSITIVE RESULTS:
Hollis-Eden Pharmaceuticals, Inc. (HEPH) announced
new preclinical data with its drug candidate HE3235 for the treatment of cancer. Data reported
this week in an oral presentation at the 4th International Conference on Tumor Progression &
Therapeutic Resistance, held October 4-5, 2007 in Philadelphia, Pennsylvania, demonstrated
that HE3235 significantly inhibited tumor growth in a preclinical model of hormone-independent
prostate cancer utilizing human tumor cells. Hormone independent tumors are associated with
late-stage prostate cancer, a condition for which there currently is no effective treatment.